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687Abstracts
OBJECTIVES: To determine in Italy the incremental cost per life
year saved (ICLYS) of clopidogrel versus ASA in secondary pre-
vention of ischemic stroke (IS), myocardial infarction (MI), or
vascular death in four high risk atherothrombotic populations:
1) with prior IS or MI to index event; 2) treated for hypercho-
lesterolemia and/or with diabetes; 3) polyvascular; and 4) with
prior cardiac surgery (CABG). METHODS: The economic
analysis was performed from the Italian Health Care System per-
spective using only direct medical costs. A Markov model
designed with 7 clinical states calculated ICLYS as the cost
needed to achieve an extra life year with a two-year treatment
with clopidogrel compared to ASA, over a lifetime horizon. The
model combined clinical outcomes from the CAPRIE trial data-
base and survival data derived from the Saskatchewan database.
The costing of events, including acute care and two-year follow-
up, was evaluated using ofﬁcial data for DRGs, tariffs and/or
charges (physicians fees, examinations, lab tests). A discount rate
of 3% was applied to costs and lifetime effects. RESULTS: Per
1000 patients treated with clopidogrel the additional ischemic
events avoided and the gain in life years were: 27 events and 119
years in prior IS or MI patients; 28 events and 130 years in
hypercholesterolemic and/or diabetic patients; 24 events and 138
years in polyvascular patients; 82 events and 474 years in prior
CABG patients. The ICLYS of clopidogrel compared to ASA
were 9055€ in prior IS or MI group, 7880€ in patients treated
for hypercholesterolemia and/or diabetes, 8216€ in polyvascular
patients and 2001€ in CABG patients. Results were robust under
a wide variation of key parameters. CONCLUSION: In Italy a
two-year treatment with Clopidogrel as an alternative to ASA is
a cost-effective strategy in secondary prevention of ischemic fatal
and non-fatal events for high-risk atherothrombotic patients.
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OBJECTIVES: The CURE study has demonstrated that treat-
ment strategy involving clopidogrel plus aspirin, comparing to
aspirin alone, signiﬁcantly reduced the risk of cardiovascular
death, myocardial infarction and stroke in patients with ACS
without ST-segment elevation. For every 1000 patients treated
with clopidogrel there were 20 less strokes, myocardial infarc-
tions or cardiovascular deaths (crude NNT = 50). The purpose
of the present study was to evaluate cost-effectiveness of clopi-
dogrel in Poland based on CURE trial efﬁcacy data. METHODS:
Data on resource use i.e. hospitalizations, medical procedures,
concomitant medications and study drug were derived from case
report form of CURE trial. Unit costs were calculated using
drugs retail prices and medical procedures tariffs contracted by
National Health Found. Cost-effectiveness was expressed as cost
per cardiovascular event avoided. The time horizon was the
mean study duration of 9 months. All costs are expressed in
EURO and EURO-PPP (1EURO = 2.08 PLN’ PPP2003).
RESULTS: Mean direct treatment cost per patient was higher in
clopidogrel than control group (2395 and 1931€; 5074€, and
4100€, PPP, respectively). The observed difference was attribut-
able mostly to a higher acquisition cost of clopidogrel. The mean
cost of initial and subsequent hospitalizations (including study
drug) was reduced for clopidogrel group by 18 and 24€, 40, and
53€-PPP, respectively. The estimated incremental cost per event
avoided amounted to 23,076€ and 48,497 EURO-PPP. CON-
CLUSIONS: Treatment with clopidogrel resulted in reduction of
initial and subsequent hospitalizations costs. The cost per event
avoided with clopidogrel in patients with ACS is consistent with
results from other countries and compares well to other treat-
ment strategies in patients with cardiovascular disease.
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OBJECTIVES: Results from the PCI-CURE trial demonstrated
that treatment strategy involving clopidogrel plus aspirin, com-
paring to aspirin alone, signiﬁcantly reduced the risk of cardio-
vascular death, myocardial infarction and stroke in patients with
acute coronary syndromes (ACS) without ST-segment elevation
undergoing percutaneous coronary interventions (PCI). The
purpose of the present study was to evaluate cost per event
avoided in the PCI subgroup of CURE trial, in Poland.
METHODS: Data on resource use, i.e. hospitalizations, medical
procedures, concomitant medications and study drug were
derived from case report form of PCI-CURE trial. Unit costs
were calculated using drugs retail prices and medical procedures
tariffs contracted by National Health Found. Cost-effectiveness
was expressed as cost per cardiovascular event avoided. The time
horizon was the mean study duration of 8 months. All costs are
expressed in EURO and EURO’PPP (1€ = 2.08 PLN’ PPP2003).
RESULTS: Mean direct treatment cost per patient was higher 
in clopidogrel than control group (2700 and 2248€, 5711, and
4759€’PPP, respectively). The observed difference was attribut-
able mostly to a higher acquisition cost of clopidogrel. The mean
cost of initial hospitalizations (including study drug) was reduced
for clopidogrel group by 26€, 57€’PPP. The estimated incremen-
tal cost per event avoided amounted to 12,858€, 27,043€’PPP.
CONCLUSIONS: Treatment with clopidogrel resulted in reduc-
tion of initial hospitalizations costs. The cost per event avoided
with clopidogrel in patients undergoing a PCI is comparable to
other interventions in this area considered as cost-effective.
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OBJECTIVE: to perform cost-effectiveness analysis of alteplase
compared with streptokinase and absence of thrombolytical
therapy for myocardial infarction (MI) in Russia. METHODS:
Data on effectiveness of treatment and resource use were
extracted from hospital medical charts randomly selected from
10 city hospitals in a retrospective study. A total of 133 patients
received alteplase, 97 patients received streptokinase and 131
patients did not receive thrombolytical therapy. Effectiveness was
assessed by death rate, presence of anginal pains, arrhythmia and
heart failure at discharge. Direct medical costs were calculated
on the basis of price-lists for medical services of an insurance
company and median prices for drugs given in a wholesale phar-
maceutical informational bulletin. Incremental cost-effectiveness
ratio (ICER) was calculated for alteplase vs streptokinase and no
thrombolytical therapy and for streptokinase vs no thrombolyt-
ical therapy. RESULTS: There was no signiﬁcant difference in
death rate between 3 groups. Patients from alteplase group sig-
niﬁcantly less often had heart failure by the end of hospital treat-
